| Project/Area Number |
20591719
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIKAWA Ryo 埼玉医科大学, 医学部, 教授 (90237678)
MATSUTANI Masao 埼玉医科大学, 医学部, 教授 (90010454)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | グリオーマ / 脳腫瘍 / MGMT / テモゾロミド / メチル化 |
|---|
| Research Abstract |
Establishment of quantitative assessment of O^6-methylguanine-DNA methyltransferase(MGMT) promoter methylation, which is prognostic and chemosensitive molecular marker in high-grade gliomas. Gliomas with MGMT methylation less than 40% showed significantly short progression-free survival. The frequency of MGMT promoter methylation in newly diagnosed pediatric glioma, regardless tumor grades, was lower than the proportion seen in adult glioma.
|
